Answer
Baricitinib is indicated for adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).
Sources for this answer
- Baricitinib LillyEli Lilly and Company Limited · emc · SmPC §4.1 Therapeutic Indications · Version 6Document updated
Sources checked